Strategic partnerships Amphista has strong backing from Advent Life Sciences and notable investors including Lilly, Forbio/Verge, Gilde Healthcare, and Novartis Venture Fund, signaling a robust funding runway and potential for co-development or licensing deals to accelerate IND filings and pipeline expansion.

Innovative platform The company focuses on bifunctional Targeted Glue therapeutics via the proprietary Eclipsys platform, offering differentiated mechanisms beyond traditional degraders, presenting opportunities for collaboration on novel targets and unmet-disease areas likely to interest pharma partners seeking unique modalities.

Clinical momentum Recent milestones include SMARCA2 degraders and AMX-883 programs with upcoming IND filing preparations, plus AACR data presentations, indicating a move toward first-in-class or best-in-class candidates suitable for licensing, collaborating, or strategic partnering to accelerate clinical development.

Market fit & demand Targeted protein degradation space remains high growth with unmet medical needs; Amphista’s non-cereblon/non-VHL glide degrader approach positions it to address resistance and broaden target space, aligning with biotech and pharma buyers seeking diversification of TPD portfolios.

Engagement channels Active participation in major conferences and ongoing investor communications, plus an established web presence, suggests ready-made avenues for outreach, joint venture discussions, and co-development talks with potential collaborators already tracking their progress.